Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Nobody home bought in yesterday @ 64.00 lokks like a good stock we will see..
Was not in it for this...missed it completely
Radius Health Up on Positive Data on Fracture Candidate......Zacks headline. Sweet.
dude!!!!!!!!
$RDUS - $41.26 +3.27 (+8.61%) WEEEEEEEEEEEEEE!
Glad I reloaded @ $37
Not a clue...but I'm comforted by the recent insider buying
Thanks Star!
So; when do you think they will receive clearance for the osteoporosis drug?
Thanks!
Mike
Radius Health Announced Today That it Has Acquired the License to Develop and Market RAD1901 in Japan, and Has Hired Dinesh Purandare, Former Sanofi Oncology Executive to the Position of Senior Vice President (SVP) and Head of Global Oncology at Radius
8:00 AM ET 3/9/15 | GlobeNewswire
Radius Health, Inc. (Nasdaq:RDUS), a science-driven biopharmaceutical company developing new therapeutics for patients with advanced osteoporosis as well as other serious endocrine-mediated diseases including hormone responsive cancers, today announced several updates for the investigational drug RAD1901, and its oncology business. RAD1901 is being evaluated at high doses as a SERD for potential use in metastatic breast cancer and at lower doses as a SERM for vasomotor symptoms. Radius announced today that it has obtained a license to develop and market RAD1901 in Japan from Eisai. On June 29, 2006, Radius had acquired the ex-Japan rights to RAD1901 and now has the full global rights to develop and commercialize this potential new therapy. Terms were not disclosed for the acquisition of Japanese rights to RAD1901.
Radius Health also continues to build its senior corporate leadership team, and expand its presence in oncology. To that end, the company is pleased to announce that on March 18, Dinesh Purandare will join as SVP and Head of Global Oncology, reporting to Radius President and CEO Robert E. Ward. Most recently, Dinesh was Vice President and Project Head for Sanofi Oncology based in Cambridge, MA. Prior to that he led the Global Oncology Marketing for Sanofi. Oncology. Prior to joining Sanofi, Dinesh served as VP and Head of Oncology Center of Excellence at the GSK Headquarters in the UK.
"We are excited to have attracted such an experienced and respected leader in oncology as Dinesh with deep knowledge of development, commercialization, and market access," said Radius Health CEO, Robert E. Ward. "Over his career, he has served as the brand CEO in bringing multiple tumor therapeutics from development through the full commercial life cycle. Dinesh leads several successful product launches including Aromasin and Tyverb in breast cancer and his experience and capabilities will be immensely valuable as we continue the development of RAD1901 in breast cancer in major markets around the world, now including Japan."
About The Investigational Drug RAD1901
Radius is developing the investigational agent RAD1901 as a potential treatment for estrogen positive (ER+) cancers, like breast, ovarian or endometrial cancer. Currently we are focusing our clinical research activities in breast cancer. The National Cancer Institute estimates that approximately 70% of breast cancers are ER+ and may grow in response to exposure to estrogen. Endocrine therapy is intended to block the estrogen signal or reduce the production of estrogen. More information about breast cancer and endocrine therapy may be found on the National Cancer Institute website http://www.cancer.gov/cancertopics/factsheet/Therapy/hormone-therapy-breast.
RAD1901 is an investigational, non-steroidal small molecule that is designed to selectively bind and degrade the estrogen receptor. RAD1901 has demonstrated potent anti-tumor activity in xenograft models of ER+ breast cancer in preclinical testing and complete suppression of the FES-PET signal after six days of dosing in a maximum tolerated dose clinical study. In preclinical models thus far, RAD1901 has shown good tissue selectivity, does not appear to stimulate the uterine endometrium, and appears to protect against bone loss in an ovariectomy-induced osteopenia rat model. In addition, we believe that RAD1901 also has the ability to cross the blood-brain barrier. In vitro, treatment of human breast cancer cell lines with the investigational drug RAD1901 resulted in degradation of the ER and inhibition of both basal and estradiol-stimulated proliferation.
Radius is recruiting patients for a Phase 1 multicenter, open-label, two-part, dose-escalation study of the investigational drug RAD1901 in postmenopausal women with advanced estrogen receptor positive and HER2-negative breast cancer. The study is designed to determine the recommended Phase 2 dose of RAD1901, and includes a preliminary evaluation of the potential anti-tumor effects. The incidence of Dose Limiting toxicities will be assessed during the first 28 days. Tumor response will be evaluated in patients with measurable or evaluable disease, using RECISTv1.1 guidelines every 8 weeks until the date of first documented progression or date of death from any cause, whichever comes first, assessed up to 12 months of treatment. Plasma concentrations of RAD1901 will be assessed every 28 days for up to 12 months of treatment. The details of the planned Phase 1 study of RAD1901 in breast cancer metastases are posted on www.clinicaltrials.gov.
Radius is also developing RAD1901 at lower doses as a SERM, for the potential treatment of vasomotor symptoms. Historically, hormone replacement therapy, or HRT, with estrogen or progesterone was considered the most efficacious approach to relieving menopausal symptoms such as hot flashes. However, because of the concerns about the potential long-term risks and contraindications associated with HRT, we believe a significant need exists for new therapeutic treatment options to treat vasomotor symptoms. In a Phase 2 proof of concept study, RAD1901 at lower doses demonstrated a reduction in the frequency and severity of moderate and severe hot flashes. We intend to commence a Phase 2b trial in vasomotor symptoms in the second half of 2015.
About Radius Health
Radius is a science-driven biopharmaceutical company developing new therapeutics for patients with advanced osteoporosis as well as other serious endocrine-mediated diseases including hormone responsive cancers. Radius' lead development candidate is the investigational drug abaloparatide for subcutaneous injection, currently in Phase 3 development for potential use in the reduction of fracture risk in postmenopausal women with severe osteoporosis. The Radius clinical portfolio also includes an investigational abaloparatide transdermal patch for potential use in osteoporosis and the investigational drug RAD1901 for potential use in hormone driven, or hormone resistant, metastatic breast cancer, including breast cancer brain metastases at www.radiuspharm.com
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding the activity of RAD1901, the ability of RAD1901 to cross the blood-brain barrier and the timing of the initiation of clinical trials of RAD1901.
These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: we have no product revenues; our need for additional funding, which may not be available; we are not currently profitable and may never become profitable; restrictions imposed on our business by our credit facility, and risks related to default on our obligations under our credit facility; risks related to raising additional capital; our limited operating history; quarterly fluctuation in our financial results; our dependence on the success of abaloparatide-SC, and our inability to ensure that abaloparatide-SC will obtain regulatory approval or be successfully commercialized; risks related to clinical trials, including having most of our products in early stage clinical trials and uncertainty that results will support our product candidate claims; the risk that adverse side effects will be identified during the development of our product candidates; product candidates for which we obtain marketing approval, if any, could be subject to restrictions or withdrawal from the market and we may be subject to penalties; failure to achieve market acceptance of our product candidates; risks related to the use of our limited resources on particular product candidates and not others; delays in enrollment of patients in our clinical trials, which could delay or prevent regulatory approvals; the dependence of our drug development program upon third-parties who are outside our control; the risk that a regulatory or government official will determine that third-parties with a financial interest in the outcome of the Phase 3 study of abaloparatide-SC affected the reliability of the data from the study; our reliance on third parties to formulate and manufacture our product candidates; failure to establish additional collaborations; our lack of experience selling, marketing and distributing products and our lack of internal capability to do so; failure to compete successfully against other drug companies; developments by competitors may render our products or technologies obsolete or non-competitive; risks related to the fact that our drugs may sell for inadequate prices or patients may be unable to obtain adequate reimbursement; effects of product liability lawsuits on commercialization of our products; failure to comply with obligations of our intellectual property licenses; failure to protect our intellectual property or failure to secure necessary intellectual property related to abaloparatide-SC, abaloparatide-TD, RAD-1901 and/or RAD-140; our or our licensors' inability to obtain and maintain patent protection for technology and products; risks related to our compliance with patent application requirements; failure to protect the confidentiality of our trade secrets; risks related to our infringement of third parties' rights; risks related to employees' disclosure of former employers' trade secrets; risks associated with intellectual property litigation, including expending substantial resources and distracting personnel from their normal responsibilities; risks associated with healthcare reform; our failure to comply with healthcare laws and regulations; our exposure to claims associated with the use of hazardous materials and chemicals; inability to successfully manage our growth; risks relating to business combinations and acquisitions; our reliance on key executive officers and advisors; our inability to hire additional qualified personnel; volatility in the price of our common stock; capital appreciation is the only source of gain for our common stock; risks related to increased costs and compliance initiatives associated with operating as a public company; our directors, executive officers and principal stockholders have substantial control over us and could delay or prevent a change in control; future sales of our common stock could depress the price of our common stock; inaccurate or unfavorable information about us could cause the price of our common stock to decline; provisions in our charter documents and Delaware law could discourage takeover attempts; and our ability to use our net operating loss carryforwards and certain other tax attributes may be limited. These and other important factors discussed under the caption "Risk Factors" in our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission, or SEC, on November 10, 2014, and our other reports filed with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.
CONTACT: Investor Relations
Barbara Ryan
Clermont Partners
Partner
203-274-2825
Bryan@radiuspharm.com
http://www.globenewswire.com/newsroom/ti?nf=MTMjMTAxMjM3NTQjMzExNDk=
Radius Health Appoints Former Novartis Executive Tony Rosenberg to Board of Directors
8:01 AM ET 3/2/15 | Dow Jones
Radius Health Appoints Former Novartis Executive Tony Rosenberg to Board of Directors
WALTHAM, Mass., March 2, 2015 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven biopharmaceutical company developing new therapeutics for patients with advanced osteoporosis as well as other serious endocrine-mediated diseases including hormone responsive cancers, announced today the appointment of Tony Rosenberg to its Board of Directors. Mr. Rosenberg had a long and successful career at Novartis, most recently serving as Corporate Head of M&A and Licensing for all of Novartis. He previously held various general management and executive leadership positions, including roles in business development, strategic planning, and marketing and sales.
"It's very exciting to have someone of Tony's caliber joining our Board, including his years of expertise in strategic transactions and his deep and global knowledge in osteoporosis and oncology," said Kurt Graves, Chairman of the Board of Radius Health. "Our Board and management team are thrilled to have Tony become the newest member of the Board as we work together to guide and shape future success."
Tony Rosenberg will also be taking the role of Chair of the Strategy Committee, replacing Dr. Morana Jovan, who resigned from the Radius Board.
"The Board and I would like to thank Morana for the critical role she played in the transformation of Radius Health, and in helping to advance us to the stage where we are on the cusp of submitting abaloparatide for registration in the US and EU," said Robert E. Ward, President and CEO of Radius Health.
Tony Rosenberg first joined Sandoz in the UK in1980 where he held various leadership positions in sales and marketing, business development and strategic planning. In 1994, he moved to Basel, initially in international product marketing, and after undertaking roles of increasing responsibility, he was named Head Global Marketing Primary Care. In 2000, Tony was named Global Head of the Transplant and Immunology Business Unit, and in 2005 he was appointed Global Head Business Development & Licensing (Pharma). In this role, Tony managed major in-licensing transactions in the cardiovascular, CNS, respiratory, infectious disease and oncology areas, as well as divestitures, mergers, and acquisitions. In 2013, he was appointed as Corporate Head of M&A and Licensing. Most recently, Tony was responsible for the Portfolio Transformation transactions undertaken by Novartis. Tony Rosenberg has a BSc (Biological Sciences) University of Leicester, and an M.Sc (Physiology) University of London.
About Radius Health
Radius is a science-driven biopharmaceutical company developing new therapeutics for patients with advanced osteoporosis as well as other serious endocrine-mediated diseases including hormone responsive cancers. Radius' lead development candidate is the investigational drug abaloparatide subcutaneous injection, currently in Phase 3 development for potential use in the reduction of fracture risk in postmenopausal women with severe osteoporosis. The Radius clinical portfolio also includes an investigational abaloparatide transdermal patch for osteoporosis and the investigational drug RAD1901 for potential use in hormone driven, or hormone resistant, metastatic breast cancer, including breast cancer brain metastases. www.radiuspharm.com
CONTACT: Investor Relations
Barbara Ryan
bryan@radiuspharm.com
(203)274-2825
> Dow Jones Newswires
March 02, 2015 08:01 ET (13:01 GMT)
Radius-Health to Announce Fourth-Quarter and Full-Year 2014 Financial-Results, Host Conference Call and Live Webcast on March 10, 2015
$RDUS - $50.09 +2.39 (+5.01%) weeeeeeeeeeeeeeeeeeeeeeeeeeeeeee!!!!!!
Shares of Radius Health Inc Soars by 24.68% for the Week
http://www.ashburndaily.com/shares-of-radius-health-inc-soars-by-24-68-for-the-week/311868/
Radius Health Inc Price Target Update
by Thomas Lindt on January 21, 2015
Radius Health Inc (NASDAQ:RDUS) should head towards $39.33 per share according to 3 Analysts in consensus. However, if the road gets shaky, the stock may fall short to $21 per share. The higher price estimate target is at $52 according to the Analysts.
Many Analysts from different Brokerage Firms have commented on the company rating and price targets.Cantor Fitzgerald maintains their rating on the shares of Radius Health Inc (NASDAQ:RDUS). The current rating of the shares is Buy. Equity Analysts at the Firm raises the price target to $26 per share from $20 per share.
Radius Health Inc (NASDAQ:RDUS) reported a drop of 9.6% or 65,835 shares in its short interest. The short figure came in at 5.8% of the total floats. The average daily volume of 633,924 shares suggests that the days to cover 618,474 short positions, as on December 31,2014, will be 1. On December 15,2014, the short interest was 684,309 shares.
Radius Health Inc (NASDAQ:RDUS) evaporated 0.05% of its value till the close of todays session. The stock opened for trading at $39.19 and the buyers never looked optimistic as the price failed to advance beyond $39.9999. However, the bears used this as an opportunity to sell and the counter continued digging deeper into the red until it hit a low of $37.11. The last exchange occurred at $39.37 with the 662,523 shares exchanging hands. The stock has earlier closed at $39.39. The 52-week high of the share price is $44.67 while the yearly low of the stock is $7.46.
http://wallstreetpulse.org/radius-health-inc-price-target-update/39876/
weeeeeeeeeeeee!!!!
Radius Announces Follow-Up on the Positive Phase 3 Top-Line Results for Its Investigational Drug Abaloparatide-SC in Postmenopausal Women With Severe Osteoporosis
Jan 12, 2015 07:00:00 (ET)
Radius Announces Follow-Up on the Positive Phase 3 Top-Line Results for Its Investigational Drug Abaloparatide-SC in Postmenopausal Women With Severe Osteoporosis
WALTHAM, Mass., Jan. 12, 2015 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS) today announced a series of follow-ups on the positive top-line 18-month fracture results that the Company announced on December 21, 2014, from its Phase 3 clinical trial (ACTIVE) evaluating the investigational drug abaloparatide-SC for potential use in the reduction of fractures in postmenopausal osteoporosis.
Radius is appreciative to have recently received feedback from the Food and Drug Administration (FDA) on the draft Statistical Analysis Plan (SAP) for the ACTIVE trial, which the Company had submitted to the FDA for regulatory input. In its response to the draft SAP, FDA requested that additional and modified analyses of the ACTIVE top-line results be performed. Radius has conducted those analyses and remains on track for submission of the NDA for abaloparatide-SC to the FDA (and MAA to the European Medicines Agency) in the second half of 2015. Radius is pleased to continue partnering with FDA in the course of our ongoing regulatory dialogue regarding the ACTIVE clinical trial and its extension study, ACTIVExtend. The results from the ACTIVE trial and from the first six months of the ACTIVExtend trial, together with the entire data set from the abaloparatide development program, are subject to regulatory review.
About the Investigational Drug Abaloparatide
Radius' investigational drug abaloparatide is a synthetic peptide analog of human parathyroid hormone-related protein (hPTHrP), a naturally occurring bone-building hormone that we believe has the potential to increase bone mineral density by stimulating new bone formation. Abaloparatide-SC is an investigational drug currently in Phase 3 development for potential use as a daily self-administered injection for the treatment of patients with postmenopausal osteoporosis at high risk of fracture. Radius also is developing the investigational drug abaloparatide-TD for potential use as a short wear-time transdermal patch designed to administer abaloparatide without the need for subcutaneous injection based on 3M's patented Microstructured Transdermal System technology.
About Radius Health
Radius is a science-driven biopharmaceutical company developing new therapeutics for patients with advanced osteoporosis as well as other serious endocrine-mediated diseases including hormone responsive cancers. Radius' lead development candidate is the investigational drug abaloparatide for subcutaneous injection, currently in Phase 3 development for potential use in the reduction of fracture risk in postmenopausal women with severe osteoporosis. The Radius clinical portfolio also includes an investigational abaloparatide transdermal patch for potential use in osteoporosis and the investigational drug RAD1901 for potential use in hormone-driven, or hormone-resistant, metastatic breast cancer, including breast cancer brain metastases.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding the expectations for the submission of an NDA for abaloparatide-SC.
These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: we have no product revenues; our need for additional funding, which may not be available; we are not currently profitable and may never become profitable; restrictions imposed on our business by our credit facility, and risks related to default on our obligations under our credit facility; risks related to raising additional capital; our limited operating history; quarterly fluctuation in our financial results; our dependence on the success of abaloparatide-SC, and our inability to ensure that abaloparatide-SC will obtain regulatory approval or be successfully commercialized; risks related to clinical trials, including having most of our products in early stage clinical trials and uncertainty that results will support our product candidate claims; the risk that adverse side effects will be identified during the development of our product candidates; product candidates for which we obtain marketing approval, if any, could be subject to restrictions or withdrawal from the market and we may be subject to penalties; failure to achieve market acceptance of our product candidates; risks related to the use of our limited resources on particular product candidates and not others; delays in enrollment of patients in our clinical trials, which could delay or prevent regulatory approvals; the dependence of our drug development program upon third-parties who are outside our control; the risk that a regulatory or government official will determine that third-parties with a financial interest in the outcome of the Phase 3 study of abaloparatide-SC affected the reliability of the data from the study; our reliance on third parties to formulate and manufacture our product candidates; failure to establish additional collaborations; our lack of experience selling, marketing and distributing products and our lack of internal capability to do so; failure to compete successfully against other drug companies; developments by competitors may render our products or technologies obsolete or non-competitive; risks related to the fact that our drugs may sell for inadequate prices or patients may be unable to obtain adequate reimbursement; effects of product liability lawsuits on commercialization of our products; failure to comply with obligations of our intellectual property licenses; failure to protect our intellectual property or failure to secure necessary intellectual property related to abaloparatide-SC, abaloparatide-TD, RAD-1901 and/or RAD-140; our or our licensors' inability to obtain and maintain patent protection for technology and products; risks related to our compliance with patent application requirements; failure to protect the confidentiality of our trade secrets; risks related to our infringement of third parties' rights; risks related to employees' disclosure of former employers' trade secrets; risks associated with intellectual property litigation, including expending substantial resources and distracting personnel from their normal responsibilities; risks associated with healthcare reform; our failure to comply with healthcare laws and regulations; our exposure to claims associated with the use of hazardous materials and chemicals; inability to successfully manage our growth; risks relating to business combinations and acquisitions; our reliance on key executive officers and advisors; our inability to hire additional qualified personnel; volatility in the price of our common stock; capital appreciation is the only source of gain for our common stock; risks related to increased costs and compliance initiatives associated with operating as a public company; our directors, executive officers and principal stockholders have substantial control over us and could delay or prevent a change in control; future sales of our common stock could depress the price of our common stock; inaccurate or unfavorable information about us could cause the price of our common stock to decline; provisions in our charter documents and Delaware law could discourage takeover attempts; and our ability to use our net operating loss carryforwards and certain other tax attributes may be limited. These and other important factors discussed under the caption "Risk Factors" in our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission, or SEC, on November 10, 2014, in our Current Report on Form 8-K filed with the SEC on the date hereof and our other reports filed with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.
CONTACT: Investor Relations
Barbara Ryan
Investor Relations
Radius Health, Inc.
203-274-2825
bryan@radiuspharm.com
(MORE TO FOLLOW) Dow Jones Newswires
January 12, 2015 07:00 ET (12:00 GMT)
Radius Health Inc. (RDUS) Has Risen To A New All-Time High
By RTT News, January 05, 2015, 10:19:00 AM EDT
Read more: http://www.nasdaq.com/article/radius-health-inc-rdus-has-risen-to-a-new-alltime-high-20150105-00703#ixzz3Ny4fhJz0
RDUS want to hit that target baby
Radius Health (RDUS) PT Raised to $45 at Jefferies
http://www.streetinsider.com/Analyst+Comments/Radius+Health+(RDUS)+PT+Raised+to+$45+at+Jefferies/10119211.html
oh, my gosh.......incredible.
$RDUS - $42.096 +10.066 (+31.43%) WEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEE!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
This article was written a little early today lol
Radius Health, Inc. RDUS 21.92% shares rose 14.43% to $36.65. The volume of Radius Health shares traded was 833% higher than normal. Radius Health reported positive Phase 3 top-line results for its investigational drug abaloparatide-sc in postmenopausal women with severe osteoporosis.
Read more: http://www.benzinga.com/news/14/12/5099961/benzingas-volume-movers#ixzz3MeHyz1cC
$$$$RDUS$$$$
$$$$RDUS$$$$
$$$$RDUS$$$$
$$$$RDUS$$$$
$$$$RDUS$$$$
so does this...
The NASDAQ OMX Group, Inc. Today Announced That Radius Health Will be Added to Its Biotechnology Index Effective Before Market Open on Monday, December 22, 2014
9:16 AM ET 12/15/14 | GlobeNewswire
-- As a result of the annual re-ranking of the NASDAQ Biotechnology Index, NASDAQ announced today that Radius Health shares will be added to the index effective before the market open on Monday, December 22, 2014.
Radius Health, Inc. (Nasdaq:RDUS) will be added to the NASDAQ Biotechnology Index (Nasdaq:NBI) before market open on Monday, December 22, 2014.
The NASDAQ Biotechnology Index is designed to track the performance of a set of securities listed on The NASDAQ Stock Market (NASDAQ) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB).
About Radius Health
Radius is a science-driven biopharmaceutical company developing new therapeutics for patients with advanced osteoporosis as well as other serious endocrine-mediated diseases including hormone responsive cancers. Radius' lead development candidate is the investigational drug abaloparatide (BA058) for subcutaneous injection, currently in Phase 3 development for potential use in the reduction of fracture risk in postmenopausal women with severe osteoporosis. The Radius clinical portfolio also includes an investigational abaloparatide transdermal patch for osteoporosis and the investigational drug RAD1901 for hormone driven, or hormone resistant, metastatic breast cancer, including breast cancer brain metastases. www.radiuspharm.com
View data
CONTACT: Investor Relations Barbara Ryan FTI Consulting Managing Director 212-850-5679 Barbara.Ryan@fticonsulting.com Media Relations Kimberly Ha FTI Consulting Senior Director 212-850-5612 Kimberly.Ha@fticonsulting.com
http://www.globenewswire.com/newsroom/ti?nf=MTMjMTAxMTIzNDkjMzExNDk=
Nice. Sure ties in to the share price rise last week.
Radius Health announces positive Phase 3 top-line results for its investigational drug abaloparatide-sc in postmenopausal women with severe osteoporosis
5:56 AM ET 12/22/14 | Briefing.com
On the primary endpoint, the investigational drug abaloparatide-SC (n=690, fracture rate 0.72%) achieved a statistically significant 83% reduction of incident vertebral fractures as compared to the placebo-treated group (n=711, fracture rate 4.36%) (p<0.0001). The ACTIVE trial included an open-label teriparatide [rDNA origin] injection treatment group (n=717, fracture rate 0.98%) that showed a statistically significant 78% reduction of incident vertebral fractures as compared to the placebo-treated group (p<0.0001). On the secondary endpoints as compared to placebo, abaloparatide-SC achieved a statistically significant fracture-rate reduction of 43% in the adjudicated non-vertebral fracture subset of patients; a statistically significant reduction of 41% in the adjudicated clinical fracture group, which includes both vertebral and non-vertebral fractures; and a statistically significant difference in the time to first incident non-vertebral fracture in both the adjudicated non-vertebral fracture and the clinical fracture subset of patients.
"We are on track for NDA submission in the second half of 2015 and encouraged by the consistency of our Phase 3 results with those from our two Phase 2 studies...These results reinforce the emerging profile of abaloparatide, and we eagerly await the first six-month results from the ongoing ACTIVExtend trial expected in the second quarter of 2015."
Radius Health (RDUS) IND for RAD1901 Accepted by FDA
http://www.streetinsider.com/Corporate+News/Radius+Health+(RDUS)+IND+for+RAD1901+Accepted+by+FDA/10112927.html
This is a monster stock to trade
whoa...nice day...good for you!
$$$F@CK YE$$$$$$$$$$!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
The NASDAQ OMX Group, Inc. Today Announced That Radius Health Will be Added to Its Biotechnology Index Effective Before Market Open on Monday, December 22, 2014
9:16 AM ET 12/15/14 | GlobeNewswire
-- As a result of the annual re-ranking of the NASDAQ Biotechnology Index, NASDAQ announced today that Radius Health shares will be added to the index effective before the market open on Monday, December 22, 2014.
Radius Health, Inc. (Nasdaq:RDUS) will be added to the NASDAQ Biotechnology Index (Nasdaq:NBI) before market open on Monday, December 22, 2014.
The NASDAQ Biotechnology Index is designed to track the performance of a set of securities listed on The NASDAQ Stock Market (NASDAQ) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB).
About Radius Health
Radius is a science-driven biopharmaceutical company developing new therapeutics for patients with advanced osteoporosis as well as other serious endocrine-mediated diseases including hormone responsive cancers. Radius' lead development candidate is the investigational drug abaloparatide (BA058) for subcutaneous injection, currently in Phase 3 development for potential use in the reduction of fracture risk in postmenopausal women with severe osteoporosis. The Radius clinical portfolio also includes an investigational abaloparatide transdermal patch for osteoporosis and the investigational drug RAD1901 for hormone driven, or hormone resistant, metastatic breast cancer, including breast cancer brain metastases. www.radiuspharm.com
View data
CONTACT: Investor Relations Barbara Ryan FTI Consulting Managing Director 212-850-5679 Barbara.Ryan@fticonsulting.com Media Relations Kimberly Ha FTI Consulting Senior Director 212-850-5612 Kimberly.Ha@fticonsulting.com
http://www.globenewswire.com/newsroom/ti?nf=MTMjMTAxMTIzNDkjMzExNDk=
weeeeeeeeeeee! This stock is awesome!
Wow...grab 1000 of this at the right spot and it's one bad ass day trading stock!
Bought in today
It will be interesting to see what happens......
what i love about this stock is the low OS there's 29mil... 21mil own by institutions
we're on our way this is a good stock to own Abolaparatide SC will become the 1st choice for osteoporosis treatment in 2016
the market is recognizing this although volume is light what happens when we trade in the millions there's only 7million shares in non-institution's hands... stock will continue 2 go up
Followers
|
9
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
116
|
Created
|
11/07/12
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |